Search

Your search keyword '"MORISCO, FILOMENA"' showing total 99 results

Search Constraints

Start Over You searched for: Author "MORISCO, FILOMENA" Remove constraint Author: "MORISCO, FILOMENA" Publisher elsevier b.v. Remove constraint Publisher: elsevier b.v.
99 results on '"MORISCO, FILOMENA"'

Search Results

1. Landscape of alcohol-related hepatocellular carcinoma in the last 15 years highlights the need to expand surveillance programs

2. Performance of the model for end-stage liver disease score for mortality prediction and the potential role of etiology

3. An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs

4. On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites

8. Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV

9. Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma

10. Characteristics of liver cirrhosis in Italy: Evidence for a decreasing role of HCV aetiology

11. Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: A multicentre study

13. Estimation of lead-time bias and its impact on the outcome of surveillance for the early diagnosis of hepatocellular carcinoma

14. Identification of naïve HCV-1 patients with chronic hepatitis who may benefit from dual therapy with peg-interferon and ribavirin

15. The unhealthy lifestyle in primary biliary cholangitis: An enemy to fight.

17. WED-414 Demographic, virological and clinical features of patients with chronic hepatitis delta treated with bulevirtide: a multicenter italian study (d-shield)

19. THU-093 Biochemical response and liver stiffness variation over time predict liver-related events in patients with primary biliary cholangitis treated with Obeticholic acid

20. FRI-078-YI Long-term albumin administration in outpatients with decompensated cirrhosis and diabetes mellitus: post-hoc analysis of the ANSWER trial database

21. LBP-038 Expanding knowledge regarding real-world treatment of patients with primary biliary cholangitis with obeticholic acid from the Italian RECAPITULATE cohort

23. Vascular liver diseases: A sex-oriented analysis of the literature.

24. Potential feasibility of atezolizumab-bevacizumab therapy in patients with hepatocellular carcinoma treated with tyrosine-kinase inhibitors.

25. THU403 - Resistance and phylogenetic analysis in HCV-2c infected patients within the Italian network VIRONET-C

26. Sarcopenia in chronic advanced liver diseases: A sex-oriented analysis of the literature.

27. Performance of the model for end-stage liver disease score for mortality prediction and the potential role of etiology

29. Surveillance for hepatocellular carcinoma with a 3-months interval in "extremely high-risk" patients does not further improve survival.

30. Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens?

31. SAT599 - Type 2 diabetes combined with portal vein tumor thrombosis worsens prognosis in patients with hepatocellular carcinoma

32. SAT535 - Correction and prevention of hyponatremia in patients with cirrhosis and ascites-post hoc analysis of the ANSWER study database

34. Hepatitis B vaccine coverage and risk factors for lack of vaccination in subjects with HBsAg negative liver cirrhosis in Italy: still, much work should be done.

35. Comparison of prognostic models in advanced hepatocellular carcinoma patients undergoing Sorafenib: A multicenter study.

36. Corrigendum to ‘An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs’ [J Hepatol 2021;75(3):572–581]

37. Effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients: Results of the Italian cohort of a post-marketing observational study.

38. Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV

39. Non-alcoholic fatty liver disease in an area of southern Italy: main clinical, histological, and pathophysiological aspects

40. SAT171 - Long-term albumin administration is not futile in patients with cirrhosis and uncomplicated ascites not normalizing serum albumin concentration with treatment

41. THU145 - Effective albumin concentration and albumin function improve after long-term albumin treatment in patients with decompensated cirrhosis

42. Liver stiffness assessment by transient elastography suggests high prevalence of liver involvement in common variable immunodeficiency.

43. HepaDisk – A new quality of life questionnaire for HCV patients.

44. The burden of HBV infection in HCV patients in Italy and the risk of reactivation under DAA therapy.

46. SAT-159-Genetic determinants in critical domains of NS5A are associated with genotype 1b HCV-induced hepatocellular carcinoma

47. THU-133-Resistance-guided retreatment of HCV infected patients with a previous failure to an NS5A inhibitor-containing regimen: Italian real life experience

48. THU-117-Evaluation of risk factors associated with failure to a first-line NS5A-containing regimen in HCV-infected patients naive to direct acting antivirals: Particular focus on natural resistance

49. PS-083-Serum albumin concentration as guide for long-term albumin treatment in patients with cirrhosis and uncomplicated ascites: Lessons from the ANSWER study

50. Awareness of individual goals, preferences, and priorities of persons with severe congenital haemophilia A for a tailored shared decision-making approach to liver-directed gene therapy. A practical guideline.

Catalog

Books, media, physical & digital resources